JNJ-5207852
Appearance
(Redirected from JNJ 5207852)
Names | |
---|---|
Preferred IUPAC name
1-(3-{4-[(piperidin-1-yl)methyl]phenoxy}propyl)piperidine | |
Identifiers | |
3D model (JSmol)
|
|
Abbreviations | JNJ-5207852 |
ChEMBL | |
ChemSpider | |
MeSH | JNJ-5207852 |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C20H32N2O | |
Molar mass | 316.480 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
JNJ-5207852 is a histamine antagonist selective for the H3 subtype. It has stimulant and nootropic effects in animal studies,[1] and has been suggested as a possible treatment for some memory defects associated with epilepsy.[2] JNJ-5207852 itself did not progress to clinical development due to poor pharmacokinetic characteristics, but the related compound JNJ-17216498 was in a Phase II clinical trial for the treatment of narcolepsy in 2007.[3]
References
[edit]- ^ Barbier AJ, Berridge C, Dugovic C, et al. (November 2004). "Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist". Br. J. Pharmacol. 143 (5): 649–61. doi:10.1038/sj.bjp.0705964. PMC 1575430. PMID 15466448.
- ^ Jia F, Kato M, Dai H, Xu A, Okuda T, Sakurai E, Okamura N, Lovenberg TW, Barbier A, Carruthers NI, Iinuma K, Yanai K (Mar 2006). "Effects of histamine H(3) antagonists and donepezil on learning and mnemonic deficits induced by pentylenetetrazol kindling in weanling mice". Neuropharmacology. 50 (4): 404–11. doi:10.1016/j.neuropharm.2005.09.017. PMID 16310812. S2CID 39844562.
- ^ Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD (July 2008). "The histamine H3 receptor: an attractive target for the treatment of cognitive disorders". Br. J. Pharmacol. 154 (6): 1166–81. doi:10.1038/bjp.2008.147. PMC 2483387. PMID 18469850.